Test Code: 13222

References

  1. Bellomo D, Arias-Mejias SM, Ramana C, et al. Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. JCO Precis Oncol. 2020;4:319-334. doi:10.1200/po.19.00206
  2. Gershenwald JE, Scolyer RA, Hess KR, et al: Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin 2017;67(6):472-492. doi:10.3322/caac.2140910
  3. National Comprehensive Cancer Network. NCCN Guidelines: Cutaneous Melanoma, Version 3 (2023) ME-F: 1 0f 3. Fort Washington US: NCCN. 2023
  4. Stassen RC, Mulder EEAP, Mooyart AL, et al. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: a multicenter prospective Dutch study. European Journal of Surgical Oncology 2023. DOI:https://doi.org/10.1016/j.ejso.2023.107249
  5. Eggermont AMM, Bellomo D, Arias-Mejias SM et al. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. Eur J Cancer. 2020;140:11-18. doi:10.1016/j.ejca.2020.08.029
  6. Mulder EEAP, Johnasson I, Grunhagen D et al. Using a clinicopathologic and gene expression (CP-GEP_ Model to identify stage I-II melanoma patients at risk of disease relapse. Cancers (Basel). 2022;14(12):2854. doi:10.3390/cancers14122854
  7. Amaral T, Sinnberg T, Chatziioannou E, et al. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Euro J Cancer 2023;182:155-162. doi:10.1016/j.ejca.2022.12.021
  8. Yu WY, Meves A, Hill S, et al. Long-term survival of melanoma patients stratified by a clinicopathologic and gene expression profile (CP-GEP model): a multi-center United States cohort study. Society for Melanoma Research Annual Meeting 2023
  9. Morton DL, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Engl. J. Med. 2014;370(7):599-609. doi:10.1056/NEJMoa1310460
  10. Centers for Medicare & Medicaid Services. MolDX: Melanoma risk stratification molecular testing. Accessed December 1, 2023. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37725&ver=38&proposedStatus=all&sortBy=title&bc=9%C2%A0
  11. Moody JA, Ali RF, Carbone AC, et al: Complications of sentinel lymph node biopsy for melanoma - a systematic review of the literature. Eur J Surg Oncol. 2017;43(2):270-277. doi:10.1016/j.ejso.2016.06.407
  12. Heiken TJ, Sadurni MB, Quattrocchi E, et al. Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study. Int J Dermatol. 2022;61(7):848-854. DOI:10.1111/ijd.16056
  13. Thao V, Dholakia R, Moriarty JP, etc. Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis. Int J Dermatol. 2023;62(1):56-61. DOI:10.1111/ijd.16515
  14. Arias-Meijias SM, Quattrocchi E, Tempel D, et al. Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study. Int J Dermatol 2020;59(11):e431-e433. doi:10.1111/ijd.14987
  15. Yousaf A, Tjien-Fooh FJ, Rentroia-Pacheo B, et al. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study. Int J Dermatol. 2021:60(7):851-856. doi:10.1111/ijd.15594
  16. Mulder EEAP, Dwarkasing JT, Tempel D, et al. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma. Br J Dermatolo. 2021;184(5):944-951. doi:10.1111/bjd.19499
  17. Johanssen I, Temple D, Dwarkasing JT, et al. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. Eur J Surg Oncol. 2022;48(2):320-3325. doi:10.1016/j.ejso.2021
  18. Alexander Meves and Alexander MM Eggermont. Deselecting melanoma patients for sentinel lymph node biopsy during COVID-19: clinical utility of tumor molecular profiling. Mayo Clin Proc Innov Qual Outcomes. 2020;4(5):586-587. doi:10.1016/j.mayocpiqo.2020.05.009

 

This FAQ is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on the physician’s education, clinical expertise, and assessment of the patient.

 

 

Document FAQS.301 Version: 0

Version 0 effective 01/29/2024 to present